Letter from the Editor

Raising the bar …

This year’s PharmaVOICE 100 issue, like so many aspects of all our lives, is set against a backdrop of unprecedented upheaval. Amid a global health crisis that is touching all corners of the world and impacting humanity in ways beyond anyone’s imagination, there is a groundswell of cultural unrest. The collision of these colossal societal contagions are creating a public health crisis the ramifications of which will be felt for years to come.

Now is the time for strong leadership, unequivocably grounded in strong science. Now is the time for courageous leadership. Now is the time for leadership without ego. Now is the time for humane leadership. Now is the time for visionary leadership.

So many of the individuals represented in this year’s PharmaVOICE 100 issue are just who we need to shepherd us through to what’s next. These leaders are emblematic of what our industy is all about — doing the right things for others. They have a sincere and passionate determination to not just do good, but to do better. Many of our showcased leaders are moving the ball forward in demonstrable ways to address COVID-19, at the same time they have not lost sight of doing what’s right to take care of their teams, their colleagues, their families, their communities, and patients. They are raising the bar and embracing the extraordinary through smart, compassionate, resilient, collaborative, and empathetic leadership.

While we do not yet know what the next weeks, months, or years will bring, we do know that because of the efforts of the inspiring leaders being recongized this year, as well as those who have been recognized in the past, we are seeing tremendous advances in science being driven by pioneering collaborations across the board. We are benefitting from much-needed disruption to antiquated processes and business models. We are witnessing an overhaul of vaccine research and development. We are seeing patients’ needs being addressed in innovative ways. We are experiencing the industry’s reputation and credibility start to return to a better place in the public’s view. These are just a few of the silver linings amid unimaginable loss and tragedy. Yet, there is a long way to go. We cannot take the spotlight off of the need for more robust conversations and policies around public health or the need for greater diversity across the board.

We will see the life-sciences industry continue to lead, continue to be a force for change, and continue to be a beacon of hope because of the collective impact of the individuals featured in this special publication as well as the thousands of like-minded visionaries around the world.

We want to thank all of you, our readers, our contributors, our advertisers for your support of this special issue, which allows us to bring these 100 amazing stories to life. We hope you will join us in celebrating this year’s esteemed group of individuals, as well as our previous
PharmaVOICE 100 honorees and Red Jacket award winners, on September 10 during our first-ever 24-Hour Celebration Marathon. Join us at pharmavoice100.com.

Taren Grom, Editor

~~~~~~~~~~~~~~~~~~~~~~~~~

Their Word…

Robin Robinson
Senior Editor

It has been an unprecedented year, and these PV100 honorees are no exception to the rule: blazing trails, innovating wonders, and improving health outcomes with their talents.

Kim Ribbink
Features Editor

This year’s PharmaVOICE 100 honorees have raised the bar for their companies, their colleagues, the industry, and for patients.

Carolyn Gretton
Features Editor

The diversity of this year’s PharmaVOICE 100, with honorees across race, gender, and orientation, reflects the wonderful complexities of the life-sciences industry they represent.

~~~~~~~~~~~~~~~~~~~~~~~~~

Coming in September

The Next Steps Forward: What’s Next post-COVID-19?
Turning Data Into Brand Stories
Health Literacy
Chief Medical Officers
Showcases:
Big Data
Digital Marketing

~~~~~~~~~~~~~~~~~~~~~~~~~

Masthead

The forum for the industry executive

Volume 20 • Number 7
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh

Senior Editor
Robin Robinson

Features Editor
Carolyn Gretton
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: [email protected].

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: [email protected].

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O. Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: [email protected].

Letters …

Send your letters to feedback@pharmavoice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.

Download PDF